若生智能
Drug Database
VA

varicella zoster immunoglobulin (VariQuin)

✓ Approved

Prothya Biosolutions · 多克隆抗体 · 多克隆抗体

什么是 varicella zoster immunoglobulin？

varicella zoster immunoglobulin 是一种多克隆抗体，由Prothya Biosolutions研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名VariQuin
公司Prothya Biosolutions
药物类别多克隆抗体, 细胞治疗, 抗体
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Prothya Biosolutions

治疗适应症

varicella zoster immunoglobulin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsVaricella zoster virus infection✓ Approved

相关研究文献

PubMedVaccines2026-07-27

Association Between Varicella Vaccination Status and Self-Reported Contact History Among Confirmed Varicella Cases in Chaoyang District, Beijing, 2017-2025.

Cao Yang Y, Wang Hao H, Zhao Ziwei Z, Li Zhen Z et al.

Objectives: To investigate associations between varicella vaccination and self-reported contact history with varicella or herpes zoster among clinically diagnosed varicella cases in Chaoyang District, Beijing, China. Methods: A retrospective observational study was conducted among 4441 clinically diagnosed varicella cases reported from 2017 to 2025. Multivariable logistic regression examined associations between vaccination status, number of doses, time since vaccination, and reported contact history with varicella and/or herpes zoster, adjusting for age, sex, and year of diagnosis. Results: Vaccinated cases had significantly higher odds of reporting contact with varicella or zoster compared with unvaccinated cases (OR = 1.34, 95% CI: 1.14-1.58). Both 1-dose and 2-dose recipients showed similar associations. A gradient of increasing odds was observed with longer time since vaccination, reaching OR = 3.17 (95% CI: 1.39-7.22) for 10 or more years since last dose. Associations were primarily driven by reported varicella contact rather than herpes zoster contact. Sensitivity analysis confirmed robustness of findings. Conclusions: Varicella vaccination was positively associated with reporting an identifiable exposure source. Vaccination status may influence completeness of exposure ascertainment in varicella surveillance and should be considered when interpreting contact tracing data.

PMID 42506654
阅读全文 →
PubMedNeurology international2026-07-27

Prognostic Factors and Clinical Characteristics of Varicella Zoster Virus Meningitis: Impact of Treatment Delay and Age-Related Differences in a Japanese Tertiary Hospital.

Tasaki Kenta K, Hara Makoto M, Nakajima Hideto H

Objectives: Varicella zoster virus (VZV) meningitis is a complication of herpes zoster that causes high rates of residual symptoms. However, prognostic factors and optimal management strategies remain unclear. This study investigated factors affecting functional outcomes, age-related differences, and the impact of prior oral antiviral therapy in VZV meningitis. Methods: This retrospective observational study enrolled patients admitted for aseptic meningitis between 2013 and 2022. The primary outcome was residual symptoms at discharge, defined as a ≥1-point increase in the modified Rankin Scale (mRS) from baseline. Multiple logistic regression identified independent risk factors. Results: Among 176 patients with aseptic meningitis, 60 (34.1%) had VZV meningitis. Patients with VZV meningitis had higher rates of residual symptoms (43.3% vs. 12.9%, p < 0.001). Independent predictors of residual symptoms included delayed intravenous acyclovir initiation (odds ratio [OR] = 1.303, 95% confidence interval [CI] = 1.060-1.601, p = 0.012), corresponding to a 30.3% increase in the odds of residual symptoms for each additional day before treatment initiation, and pre-onset mRS (OR = 2.352, 95% CI = 1.056-5.237, p = 0.036). Patients ≥ 50 years old displayed lower rates of headache (75.0% vs. 96.9%, p = 0.020), neck stiffness (25.0% vs. 62.5%, p = 0.005), and CSF pleocytosis (56/μL vs. 142/μL, p = 0.023). Prior oral antiviral therapy was not associated with a rate of residual symptoms (p = 0.795). Conclusions: Delayed initiation of intravenous acyclovir was independently associated with residual symptoms at discharge, whereas older patients often presented with atypical clinical features, requiring heightened clinical suspicion. Given the lack of observed benefit associated with prior oral antiviral therapy, prompt initiation of intravenous acyclovir should be considered when VZV meningitis is suspected.

PMID 42506052
阅读全文 →
PubMedExpert opinion on therapeutic patents2026-07-27

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage.

Gege Christian C, Kleymann Gerald G

Helicase-primase is an interesting target for small-molecule therapy of orthoherpesviruses in general and in particular herpes simplex virus (HSV) and varicella zoster virus (VZV) infections. With amenamevir already approved for the treatment of VZV and HSV in Japan and with pritelivir's granted breakthrough therapy designation and priority review for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, other companies have also expressed interest in small-molecule helicase-primase inhibitors (HPIs). We review the helicase-primase inhibitor landscape across HSV and VZV, focusing on patent coverage, key structure-activity relationships and the clinical progress of leading candidates. Following the clinical validation of the helicase-primase target by amenamevir and pritelivir, substantial patent activity has emerged around structurally diverse scaffolds aimed at enhancing target residence time, improving resistance profiles, enabling prolonged antiviral exposure and optimizing tissue distribution, including nerve penetration. In parallel, the availability of several cryo-electron microscopy structures of the helicase-primase complex has enabled structure-based and computer-aided drug design, facilitating the exploration of alternative scaffolds beyond the established chemotypes. The potential opportunities and limitations of the current HPIs, as well as the different dosage forms, are discussed.

PMID 42504102
阅读全文 →
PubMedZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]2026-07-27

[Evaluation of varicella vaccine effectiveness among children aged 1-14 years in Weifang City: a case-control study].

Wang Y Y YY, Peng P P, Tang Y J YJ, Wei J J et al.

Based on the reports from the Chinese Disease Prevention and Control Information System, 177 varicella cases among children aged 1 to 14 in Weifang City from 2022 to 2024 were selected as the case group. Through the Weifang Immunization Planning Information Platform, 708 healthy children were individually matched at a 1∶4 ratio by age, sex, and town/street and included as controls. A conditional multivariable logistic regression model was used to estimate the vaccine effectiveness (VE) of the varicella vaccine, while restricted cubic splines (RCS) were applied to analyze the dynamic changes in VE after the last dose. Results showed that the overall VE was 80.72% (95%CI: 69.16%-87.95%), with two-dose vaccination providing significantly higher protection (91.63%) than one dose (50.96%). The VE after the last dose exhibited an initial increase followed by a decline over time. In conclusion, the varicella vaccine demonstrates strong effectiveness against varicella; therefore, a two-dose vaccination strategy is recommended and should be incorporated into routine immunization programs.

PMID 42503934
阅读全文 →
PubMedVaccines2026-07-27

Real-World Safety of Concurrent Measles-Mumps-Rubella and Varicella Vaccination in Korean Infants: A Multicenter Self-Controlled Case Series Study.

Choi Sujin S, Ahn Bin B, Lee Yeonjoo Y, Kim Gwanglok G et al.

Measles, mumps, rubella (MMR) and varicella vaccines are often co-administered to optimize coverage, yet safety concerns regarding febrile convulsions persist. In South Korea, MMR and varicella vaccines are administered as separate injections during a single visit (MMR + V). This study evaluated the real-world safety of concurrent MMR + V vaccination, focusing on the domestically implemented MAV/06 and Oka-derived strains. We conducted a multicenter self-controlled case series (SCCS) study of children aged 12-23 months who received MMR + V and hepatitis A vaccine (HAV) between 2015 and 2024. Using electronic health records, we identified predefined adverse events (AEs), including fever and healthcare visits. Adjusted relative risks (aRRs) were estimated using conditional Poisson regression. Among 3035 children (52.3% male; median age, 12 months), 71.7% received the MAV/06 varicella strain. A distinct peak in AEs occurred 7-13 days after MMR + V administration, with fever showing the greatest increase (aRR, 4.27; 95% CI, 2.76-6.60). The risks of total sick visits (aRR, 2.15; 95% CI, 1.70-2.71) and acute care visits (aRR, 2.13; 95% CI, 1.46-3.10) were similarly confined to this interval and returned to baseline thereafter. Febrile convulsions were uncommon (aRR, 5.37; 95% CI, 1.20-24.01). No excess risks were observed during the HAV or overlap periods, and no synergistic effects of intensive multi-vaccine administration were detected. Concurrent administration of MMR and varicella vaccines in Korean infants-predominantly using the MAV/06 strain-was associated only with expected, transient increases in fever during days 7-13 postvaccination. No serious or sustained safety signals were identified, supporting the continued use of Korea's separate-injection MMR + V strategy.

PMID 42506590
阅读全文 →
PubMedVaccines2026-07-27

Site-Specific Glycosylation Profiling of Protein Subunit and Inactivated Virus Vaccines.

Goecker Zachary C ZC, Burke Meghan C MC, Liu Yi Y, Mirokhin Yuri A YA et al.

Background/Objectives: Glycosylation can affect vaccine antigen structure and function, making site-specific glycan characterization relevant to antigen quality and comparability. However, quantitative approaches for comparing glycan microheterogeneity remain limited. This study evaluated the utility of the glycopeptide abundance distribution spectra framework for measuring similarity among site-specific glycosylation profiles in vaccines and antigen reference reagents across manufacturing conditions. Methods: Intact N-linked glycopeptides were characterized by nanoflow liquid chromatography-tandem mass spectrometry with stepped-energy fragmentation. Products included monovalent and quadrivalent influenza antigens produced in embryonated eggs, Madin-Darby canine kidney cells, or Spodoptera frugiperda cells, together with a SARS-CoV-2 spike vaccine produced in Spodoptera frugiperda cells and a Chinese hamster ovary cell-produced varicella-zoster virus glycoprotein E vaccine. Site-specific glycan distributions were represented as distribution spectra and compared using NIST MS Search software. Dot-product scores ranging from 0 to 999 quantified similarity. Results: Across measured glycosylation sites, distributions clustered into six recurrent classes. Similarity was high for replicate analyses, conserved influenza components across annual formulations, and matched components from different suppliers within the same production platform (similarity scores = 978, 961, and 960, respectively). Similarity was lower between sites within the same protein, between influenza strains, and between production sources (similarity scores = 554, 540, and 209, respectively). Among production-source comparisons, egg- and Madin-Darby canine kidney-derived profiles were most similar, and the overall ordering of glycosylation similarity was consistent with broad phylogenetic relatedness among production hosts. Conclusions: Distribution spectra-based similarity scoring of vaccine glycoproteins provides a quantitative, reusable approach for documenting site-specific glycosylation microheterogeneity. Using this method, we can conclude that production source is the dominant contributor to variation, whereas replicates, annual formulations, and suppliers within the same production platform are highly consistent.

PMID 42506681
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多varicella zoster immunoglobulin